Los agonistas (las sustancias que se unen al receptor celular para producir una respuesta) del GLP 1 son un grupo de medicamentos que ayudan, principalmente, a controlar los niveles de azcar en la sangre (glucosa) en las personas que padecen diabetes tipo 2
The dual agonism appears to produce synergistic effects on weight loss, with clinical trials demonstrating up to ~21% body weight reduction at the 15 mg dose in people without diabetes, while weight loss is typically less in type 2 diabetes
Finally, combination therapy is more feasible in high-income settings, where healthcare systems can sustain the associated costs
Insurance coverage through plans like Anthem, UnitedHealthcare, or Aetna can significantly reduce or eliminate out-of-pocket costs
when the medication stops, when cravings return, when old habits creep in
Advances in drug development have led to dual agonists such as tirzepatide, which target both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors and produce greater weight loss than single-receptor agonists
)
)
